

CGBIO to seize Korean premium filler market

22 July 2020 | News

"High Expectations" on the Korean Aesthetics Market as big bodies collaborate to bring a new wave in the Korean Filler Market



CGBIO, first medical healthcare company to successfully develop an aesthetic premium filler 'Giselleligne' using the R2 technology, has announced a successful MOU partnership of with DNCompany, which has strong distribution and sales foundation in the aesthetics market in Korea.

CGBIO is a Korea's Regenerative Medicine company which has their own biomaterials and its patented technologies. Based on this professional medical background, CGBIO has successfully developed premium HA filler, 'Giselleligne' which provides both lifting and volume targeting patients in their 30s and 40s. In addition, 'VOM' is a younger brand focused on contouring for patients in their 20s and 30s.

GISELLELIGNE has already received approval from the National Medical Products Administration (NMPA) of China and has been launched in the premium HA filler product in the China market. It has also been registered in the Indonesia, Philippine, and Colombia markets. CGBIO plans to register this product in more than 20 countries by obtaining the CE certification of Europe and PMA approval of the U.S FDA.

CGBIO and DNCompany together will collaborate to launch the premium HA filler in the market and look forward to change the general perception in the aesthetics market that "Only foreign fillers are safe and superior than domestic fillers".

Image Caption- Hyun Seung Yu, CEO, CGBIO (left) and Jong Won SEO, CEO, DNCompany (right) signs MOU contract for collaboration